Covetrus, INC.: directors' dealings · United States · SEC (Form 4)

About Covetrus, INC.

Covetrus, Inc. (ticker: CVET) is a U.S.-based animal-health company that has historically been associated with the NASDAQ market before its delisting. For French-, Belgian- and Swiss-based investors, it can be viewed as a specialized, integrated animal-health platform rather than a pure software vendor or a pure distributor. The company was created in 2019 through the combination of Henry Schein’s animal-health business and Vets First Choice, bringing together distribution capabilities, veterinary software, and digital prescription workflows under one umbrella. ([northamerica.covetrus.com](https://northamerica.covetrus.com/resource-center/blogs/news/news/2019/02/08/covetrus-celebrates-launch-as-newly-formed-public-company?utm_source=openai)) Covetrus’ business model centers on helping veterinary practices operate more efficiently and more profitably. Its offering spans practice management software, client communications tools, payment processing, prescription management, and a broad portfolio of veterinary products, consumables, medicines, equipment, and distribution services. The company serves companion animals, equine practices, and large-animal markets, which gives it exposure across multiple veterinary end-markets. In strategic terms, Covetrus sits at the intersection of software, supply chain, and animal-health commerce. ([products.covetrus.com](https://products.covetrus.com/about)) From a geographic standpoint, Covetrus is headquartered in Portland, Maine, United States, and reports operations in 19 countries worldwide. The company states that it serves more than 100,000 customers globally and employs over 5,700 people. That international footprint matters because veterinary care models and procurement patterns differ widely by geography, and Covetrus’ scale is designed to support those differences through localized distribution and software solutions. ([products.covetrus.com](https://products.covetrus.com/about)) In competitive terms, Covetrus operates in a market that is both fragmented and highly relationship-driven. Its key differentiator is the combination of technology and logistics: by linking practice software, prescription fulfillment, customer engagement, and product distribution, it aims to become embedded in daily veterinary workflows. That integrated approach can help improve customer retention, create switching costs, and support cross-selling across software and consumables. ([products.covetrus.com](https://products.covetrus.com/about)) A major recent development came in February 2026, when Covetrus announced a definitive agreement with Cencora to merge Covetrus and MWI Animal Health into a combined animal-health platform. Management framed the transaction as a way to broaden access to products and solutions, strengthen logistics, and improve affordability and accessibility across the animal-health ecosystem. For equity investors, this is an important strategic signal: Covetrus remains a consolidation candidate and a key asset in the ongoing restructuring of the U.S. animal-health distribution and technology landscape. ([s203.q4cdn.com](https://s203.q4cdn.com/785768684/files/doc_news/Covetrus-and-MWI-Animal-Health-to-Merge-2026.pdf))